JMP Securities initiated coverage of Abivax (ABVX) with an Outperform rating and $33 price target Abivax is focused on the development and commercialization of obefazimod, a novel immune modulator for the treatment of inflammatory bowel diseases, the analyst tells investors in a research note. The firm says the company has demonstrated “robust” Phase 2b results in patients with moderate-to-severe ulcerative colitis and results from two Phase 3 induction trials are anticipated in early Q2 of 2025. It believes the commercial potential for obefazimod is “compelling.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABVX:
- Abivax Initiates $150 Million ATM Program on Nasdaq
- Abivax Reports Strong Q3 Financials and Clinical Progress
- Abivax data support potential of obefazimod as UC treatment option
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
